Hologic
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Hologic sits in the top decile of US sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count).
Hologic: 21 sponsored US clinical trials, 2 recruiting.
Hologic sponsors 21 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 16 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Screening, with 1 trials.
Top-decile sponsor footprint
Hologic ranks in the top decile of sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
16 of 19 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
21 total, page 1 of 1
Prospective Case Collection Study of Contrast-Enhanced Mammography Imaging Acquired on a New Investigational Device
NCT06636539
Prospective Case Collection Study for New Mammography Technologies
NCT05199701
A Prospective, Multi-site Clinical Study to Collect User Feedback Using Affirm® Contrast Biopsy
NCT04671329
A Post-Market Clinical Trial to Evaluate the Performance and Operation of the Brevera Breast Biopsy System
NCT03300206
Evaluating Image Quality and Comfort of an Investigational Curved Paddle Compared to a Standard Paddle
NCT03611543
Clinical Evaluation of the Aptima® Combo 2® Assay Using the Panther® System in Female Urine Samples
NCT02795975
Evaluation of the HSV 1 & 2 Assay in Specimens From Symptomatic Subjects
NCT02270099
Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay
NCT02167113
Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing
NCT02068963
Dual-energy Contrast-enhanced (2D and 3D Mammography Versus Contrast-enhanced MRI)- A Pilot Study
NCT01433640
MyoSure Hysteroscopic Tissue Removal System Registry Study
NCT01369758
Adiana Post-Approval Clinical Study (APACS)
NCT01177670
HOME Study: Hysteroscopic Office Myomectomy Evaluation
NCT01152112
Comparative Sedation Study of the MyoSure Hysteroscopic Tissue Removal System
NCT00979342
A Comparison of the 15 and 30 Acquisition Angle Breast Tomosynthesis Mammography for Breast Abnormalities
NCT00990483
Multicenter Hologic Tomosynthesis Study
NCT00971087
Comparison of Fetal Fibronectin (fFN) Specimen Collection Methodologies: With Speculum Versus Without Speculum
NCT00883324
Evaluation of a 3-D Tomosynthesis Mammography System Used in Conjunction With Conventional 2-D Digital Mammography
NCT00754598
GliaSite 1-3 Mets Study
NCT00589212
MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ
NCT00586326
Safety & Efficacy Study of the Adiana System for Women Who Desire Permanent Birth Control (Sterilization)
NCT00737061
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Therapeutic Areas
What is open in the Hologic pipeline
2 recruiting of 21 indexed (10% open); 16 completed (76%).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Breast Screening (1 trial), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Hologic: open-pipeline peers nationwide
Peers matched on 21 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Hologic sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 21 trials (± recruiting share)
- AEterna Zentaris · 21 trials · 0% recruiting
- Amphastar Pharmaceuticals · 21 trials · 5% recruiting
- Apellis Pharmaceuticals · 21 trials · 10% recruiting
- Array Biopharma, now a wholly owned subsidiary of Pfizer · 21 trials · 0% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Southern Illinois University · 10% recruiting · 21 trials
- Joslin Diabetes Center · 10% recruiting · 73 trials
- Corewell Health East · 9% recruiting · 106 trials
- Children's Oncology Group · 10% recruiting · 342 trials
Related
What to do with this Hologic page
21 registered trials is a research-attention snapshot, not an endorsement of Hologic or any single study.
- 2 of Hologic's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Screening is the condition Hologic studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Screening trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Hologic pipeline card: 21 registered trials from official public datasets.Report a data error.